Drug Profile
ATP 128
Alternative Names: ATP128; KISIMA®cancer vaccineLatest Information Update: 10 Nov 2023
Price :
$50
*
At a glance
- Originator Amal Therapeutics
- Developer Amal Therapeutics; Boehringer Ingelheim
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Protein vaccines; Recombinant fusion proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Colorectal cancer
Most Recent Events
- 20 Sep 2023 Immunogenicity data from the phase Ib/II KISIMA-01 trial in colorectal cancer presented at the 7th Annual International Cancer, Immunotherapy Conference (CRI-ENCI-AACR-2023)
- 28 Mar 2023 No recent reports of development identified for preclinical development in Colorectal-cancer in Switzerland (SC, Injection)
- 08 Apr 2022 Immunogenicity data from a phase Ib/II trial in colorectal cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)